Ruxolitinib waa molecule yar oo Janus kinase inhibitor ah oo loo isticmaalo daawaynta dhexe ama khatarta sare ee myelofibrosis iyo qaababka u adkaysta ee polycythemia vera iyo graft-vs-host disease. Ruxolitinib waxay la xiriirtaa kor u kac ku meel gaar ah oo caadi ahaan khafiif ah ee serum aminotransferase inta lagu jiro daawaynta iyo xaaladaha dhifka ah ee iskood u xaddidan, dhaawaca beerka ba'an ee caafimaad ahaan iyo sidoo kale kiisaska dib u kicinta cagaarshowga B ee shakhsiyaadka u nugul.

Ruxolitinib waa daawada afka laga heli karo ee Janus-associated kinase (JAK) inhibitor oo leh hawlo antineoplastic iyo immunomodulating suurtagal ah. Ruxolitinib wuxuu si gaar ah ugu xidhaa oo uu joojiyaa borotiinkatyrosinekinases JAK 1 iyo 2, taas oo keeni karta hoos u dhac ku yimaada caabuqa iyo xakameynta kororka unugyada. Dariiqa JAK-STAT (calaamadaha calaamadeeyaha iyo dhaqdhaqaaqa qoraalka qoraalka) waxay door muhiim ah ka ciyaaraan calaamadaha cytokines iyo arrimo badan oo koritaanka waxayna ku lug leeyihiin faafinta unugyada, koritaanka, hematopoiesis, iyo jawaabta difaaca; JAK kinase waxaa laga yaabaa in lagu hagaajiyo cudurada bararka, xanuunka myeloproliferative, iyo malignancies kala duwan.

Ruxolitinib waa apyrazoleWaxaa lagu beddelay booska 1 koox 2-cyano-1-cyclopentylethyl ah iyo booska 3 koox pyrrolo [2,3-d] pyrimidin-4-yl ah. Waxaa loo isticmaalaa sida cusbada fosfatka ee loogu talagalay daaweynta bukaanada qaba myelofibrosis dhexdhexaad ah ama khatar sare leh, oo ay ku jiraan myelofibrosis aasaasiga ah, post-polycythemia vera myelofibrosis iyo post-esential thrombocythemia myelofibrosis. Waxay leedahay door sida wakiilka antineoplastic iyo EC 2.7.10.2 (protein aan gaar ahayn-tyrosinekinase) ka hortag. Waa nitrile, apyrrolopyrimidineiyo xubin ka mid ah pyrazoles.